SCHEMBL20775124

SCHEMBL20775124

COc1ccc2c(Oc3ccc(NS(N)(=O)=O)cc3)ccnc2c1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 5/20 0.55
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
KDR P35968 8/20 0.53
PDGFRA P16234 7/20 0.53
AURKA O14965 2/20 0.52
MET P08581 2/20 0.52
TEK Q02763 2/20 0.52
AURKB Q96GD4 1/20 0.52
AXL P30530 1/20 0.51
ENPP3 O14638 1/20 0.50
ENPP1 P22413 1/20 0.50
DDR2 Q16832 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20782446 0.89 AXL (0.52) FGFR2CA1CA2KDRPDGFRA
SCHEMBL20782518 0.88 FGFR2 (0.53) FGFR2KDRPDGFRAAURKAMET
SCHEMBL20782493 0.88 FGFR2 (0.68) FGFR2KDRPDGFRAAXL
SCHEMBL22407521 0.88 ENPP3 (0.46) FGFR2CA1CA2KDRPDGFRA
SCHEMBL20782728 0.88 AXL (0.52) FGFR2CA1CA2KDRPDGFRA
SCHEMBL20782727 0.87 HPGD (0.53) FGFR2CA1CA2KDRPDGFRA
SCHEMBL20782601 0.87 AXL (0.53) FGFR2KDRMETAXL
SCHEMBL22407373 0.86 KDR (0.50) FGFR2KDRPDGFRAAURKAMET
SCHEMBL20782867 0.86 PDGFRA (0.53) KDRPDGFRAAURKAMETTEK
SCHEMBL25683666 0.84 FGFR2 (0.57) FGFR2KDRPDGFRAAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 US disclosed
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 US disclosed
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 US disclosed
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2020-09-17 US disclosed
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2020-09-17 US disclosed
EP-3676254-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF AbbVie Inc. (US) 2020-07-08 EP disclosed
WO-2019046778-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF MAVUPHARMA, INC. (US) 2019-03-07 WO disclosed
WO-2019046778-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF MAVUPHARMA, INC. (US) 2019-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 FGFR2 4496/4885CA1 4595/4885CA2 4105/4885
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 FGFR2 4496/4885CA1 4595/4885CA2 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.